{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:28:58Z","timestamp":1794018538536,"version":"4.8.0"},"reference-count":195,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T00:00:00Z","timestamp":1607990400000},"content-version":"unspecified","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,10,12]]},"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:p>Immune effector cell (IEC) therapies offer durable and sustained remissions in significant numbers of patients with hematological cancers. While these unique immunotherapies have improved outcomes for pediatric and adult patients in a number of disease states, as \u2018living drugs,\u2019 their toxicity profiles, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), differ markedly from conventional cancer therapeutics. At the time of article preparation, the US Food and Drug Administration (FDA) has approved tisagenlecleucel, axicabtagene ciloleucel, and brexucabtagene autoleucel, all of which are IEC therapies based on genetically modified T cells engineered to express chimeric antigen receptors (CARs), and additional products are expected to reach marketing authorization soon and to enter clinical development in due course. As IEC therapies, especially CAR T cell therapies, enter more widespread clinical use, there is a need for clear, cohesive recommendations on toxicity management, motivating the Society for Immunotherapy of Cancer (SITC) to convene an expert panel to develop a clinical practice guideline. The panel discussed the recognition and management of common toxicities in the context of IEC treatment, including baseline laboratory parameters for monitoring, timing to onset, and pharmacological interventions, ultimately forming evidence- and consensus-based recommendations to assist medical professionals in decision-making and to improve outcomes for patients.<\/jats:p>","DOI":"10.1136\/jitc-2020-001511","type":"journal-article","created":{"date-parts":[[2020,12,30]],"date-time":"2020-12-30T13:11:50Z","timestamp":1609333910000},"page":"e001511","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":250,"title":["Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct02535364","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01865617","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02546167","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04026737","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7578-0393","authenticated-orcid":false,"given":"Marcela V","family":"Maus","sequence":"first","affiliation":[{"name":"Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Alexander","sequence":"additional","affiliation":[{"name":"Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3979-9273","authenticated-orcid":false,"given":"Michael R","family":"Bishop","sequence":"additional","affiliation":[{"name":"Department of Medicine, The University of Chicago, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7904-8415","authenticated-orcid":false,"given":"Jennifer N","family":"Brudno","sequence":"additional","affiliation":[{"name":"Surgery Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Callahan","sequence":"additional","affiliation":[{"name":"Cancer Immunotherapy Program, Division of Oncology, Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6270-3065","authenticated-orcid":false,"given":"Marco L","family":"Davila","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Diamonte","sequence":"additional","affiliation":[{"name":"Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorg","family":"Dietrich","sequence":"additional","affiliation":[{"name":"Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie C","family":"Fitzgerald","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Critical Care, Children\u2019s Hospital of Philadelphia and University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6774-5694","authenticated-orcid":false,"given":"Matthew J","family":"Frigault","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplant and Cellular Immunotherapy Program, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry J","family":"Fry","sequence":"additional","affiliation":[{"name":"Pediatric Hematology\/Oncology\/BMT, Children\"s Hospital Colorado and University of Colorado Anschutz School of Medicine, Aurora, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1425-7002","authenticated-orcid":false,"given":"Jennifer L","family":"Holter-Chakrabarty","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology\/Bone Marrow Transplant and Cellular Therapy, The University of Oklahoma Stephenson Cancer Center, Oklahoma City, Oklahoma, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna V","family":"Komanduri","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Virginia Cancer Center, Charlottesville, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9063-6691","authenticated-orcid":false,"given":"Frederick L","family":"Locke","sequence":"additional","affiliation":[{"name":"Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon L","family":"Maude","sequence":"additional","affiliation":[{"name":"Cancer Immunotherapy Program, Division of Oncology, Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA"},{"name":"Department of Pediatrics, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9577-3879","authenticated-orcid":false,"given":"Philip L","family":"McCarthy","sequence":"additional","affiliation":[{"name":"Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Mead","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Critical Care Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sattva S","family":"Neelapu","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1513-8833","authenticated-orcid":false,"given":"Tomas G","family":"Neilan","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca D","family":"Santomasso","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J","family":"Shpall","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7373-8987","authenticated-orcid":false,"given":"David T","family":"Teachey","sequence":"additional","affiliation":[{"name":"Cancer Center, Children\u2019s Hospital of Philadelphia and University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4722-4461","authenticated-orcid":false,"given":"Cameron J","family":"Turtle","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center Division of Medical Oncology, University of Washington, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Whitehead","sequence":"additional","affiliation":[{"name":"Emily Whitehead Foundation, Phillipsburg, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8030-7595","authenticated-orcid":false,"given":"Stephan A","family":"Grupp","sequence":"additional","affiliation":[{"name":"Cancer Immunotherapy Program, Division of Oncology, Children\u2019s Hospital of Philadelphia and University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,12,16]]},"reference":[{"key":"2025100310024539000_8.2.e001511.1","unstructured":"Kite . Yescarta package insert, 2017. United States FDA. Available: https:\/\/www.fda.gov\/media\/108377\/download"},{"key":"2025100310024539000_8.2.e001511.2","unstructured":"Novartis . Kymriah package insert, 2017. United States FDA. Available: https:\/\/www.fda.gov\/media\/107296\/download"},{"key":"2025100310024539000_8.2.e001511.3","unstructured":"Kite . Tecartus package insert, 2020. United States FDA. Available: https:\/\/www.fda.gov\/media\/140409\/download"},{"key":"2025100310024539000_8.2.e001511.4","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005930"},{"key":"2025100310024539000_8.2.e001511.5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.5929"},{"key":"2025100310024539000_8.2.e001511.6","first-page":"537","article-title":"Tisagenlecleucel: the first CAR on the highway to remission for acute lymphoblastic leukemia","volume":"9","author":"Freyer","year":"2018","journal-title":"J Adv Pract Oncol"},{"key":"2025100310024539000_8.2.e001511.7","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025100310024539000_8.2.e001511.8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-519413"},{"key":"2025100310024539000_8.2.e001511.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"2025100310024539000_8.2.e001511.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103849"},{"key":"2025100310024539000_8.2.e001511.11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.8519"},{"key":"2025100310024539000_8.2.e001511.12","doi-asserted-by":"crossref","first-page":"8517","DOI":"10.1200\/jco.2015.33.15_suppl.8517","article-title":"Safety and efficacy of anti-CD19 chimeric antigen receptor (CAR)-modified autologous T cells (CTL019) in advanced multiple myeloma","volume":"33","author":"Garfall","year":"2015","journal-title":"JCO"},{"key":"2025100310024539000_8.2.e001511.13","doi-asserted-by":"crossref","first-page":"TPS7132","DOI":"10.1200\/jco.2013.31.15_suppl.tps7132","article-title":"A phase II, dose-optimization trial of autologous T cells genetically engineered to express anti-CD19 chimeric antigen receptor (CART-19) in patients with relapsed or refractory (r\/r) CD19+ chronic lymphocytic leukemia (CLL)","volume":"31","author":"Porter","year":"2013","journal-title":"JCO"},{"key":"2025100310024539000_8.2.e001511.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347"},{"key":"2025100310024539000_8.2.e001511.15","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V130.Suppl_1.740.740","article-title":"Durable clinical responses in heavily pretreated patients with relapsed\/refractory multiple myeloma: updated results from a multicenter study of bb2121 Anti-Bcma CAR T cell therapy","volume":"130","author":"Berdeja","year":"2017","journal-title":"Blood"},{"key":"2025100310024539000_8.2.e001511.16","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025100310024539000_8.2.e001511.17","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0681-6"},{"key":"2025100310024539000_8.2.e001511.18","doi-asserted-by":"publisher","DOI":"10.1042\/BST20150286"},{"key":"2025100310024539000_8.2.e001511.19","first-page":"13","article-title":"Associated toxicities: assessment and management related to CAR T-cell therapy","volume":"23","author":"Anderson","year":"2019","journal-title":"Clin J Oncol Nurs"},{"key":"2025100310024539000_8.2.e001511.20","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy1025"},{"key":"2025100310024539000_8.2.e001511.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.756"},{"key":"2025100310024539000_8.2.e001511.22","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25315"},{"key":"2025100310024539000_8.2.e001511.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"2025100310024539000_8.2.e001511.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"2025100310024539000_8.2.e001511.25","doi-asserted-by":"crossref","unstructured":"Graham R , Mancher M . Clinical practice guidelines we can trust. Washington DC: National Academies Press, 2011.","DOI":"10.17226\/13058"},{"key":"2025100310024539000_8.2.e001511.26","unstructured":"Howick J , Chalmers I , Glasziou P , et al . Explanation of the 2011 Oxford centre for evidence-based medicine (OCEBM) levels of evidence (background document), 2011 Oxford Centre for Evidence-Based Medicine. Available: https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/explanation-of-the-2011-ocebm-levels-of-evidence\/"},{"key":"2025100310024539000_8.2.e001511.27","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/s41419-018-0918-x","article-title":"The biological basis and clinical symptoms of CAR-T therapy-associated toxicites","volume":"9","author":"Titov","year":"2018","journal-title":"Cell Death Dis"},{"key":"2025100310024539000_8.2.e001511.28","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"2025100310024539000_8.2.e001511.29","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hon.2595","article-title":"Managing the toxicities of car T-cell therapy","volume":"37 Suppl 1","author":"Neelapu","year":"2019","journal-title":"Hematol Oncol"},{"key":"2025100310024539000_8.2.e001511.30","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-018-0324-z"},{"key":"2025100310024539000_8.2.e001511.31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-703751"},{"key":"2025100310024539000_8.2.e001511.32","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.20"},{"key":"2025100310024539000_8.2.e001511.33","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4597"},{"key":"2025100310024539000_8.2.e001511.34","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aat6753","article-title":"Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function","volume":"11","author":"Salter","year":"2018","journal-title":"Sci Signal"},{"key":"2025100310024539000_8.2.e001511.35","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25445"},{"key":"2025100310024539000_8.2.e001511.36","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"2025100310024539000_8.2.e001511.37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2025"},{"key":"2025100310024539000_8.2.e001511.38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"2025100310024539000_8.2.e001511.39","doi-asserted-by":"crossref","first-page":"7515","DOI":"10.1200\/JCO.2019.37.15_suppl.7515","article-title":"Lisocabtagene maraleucel (liso-cel) treatment of patients (PTS) with relapsed\/refractory (R\/R) B-cell non-Hodgkin lymphoma (NHL) and secondary CNS lymphoma: initial results from TRANSCEND NHL 001","volume":"37","author":"Abramson","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"2025100310024539000_8.2.e001511.40","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood-2019-127508","article-title":"Pivotal safety and efficacy results from Transcend NHL 001, a multicenter phase 1 study of Lisocabtagene Maraleucel (liso-cel) in relapsed\/refractory (R\/R) large B cell lymphomas","volume":"134","author":"Abramson","year":"2019","journal-title":"Blood"},{"key":"2025100310024539000_8.2.e001511.41","doi-asserted-by":"publisher","DOI":"10.3109\/10428191003661852"},{"key":"2025100310024539000_8.2.e001511.42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-234492"},{"key":"2025100310024539000_8.2.e001511.43","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/707542","article-title":"Outcome of very late relapse in patients with Hodgkin\"s lymphomas","volume":"2011","author":"Gaudio","year":"2011","journal-title":"Adv Hematol"},{"key":"2025100310024539000_8.2.e001511.44","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000151"},{"key":"2025100310024539000_8.2.e001511.45","first-page":"CD008983","article-title":"Influenza vaccines in immunosuppressed adults with cancer","volume":"2","author":"Bitterman","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2025100310024539000_8.2.e001511.46","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e3182a66b76"},{"key":"2025100310024539000_8.2.e001511.47","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41571-018-0075-2","article-title":"Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy","volume":"16","author":"Mahadeo","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"2025100310024539000_8.2.e001511.48","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-019-0580-3"},{"key":"2025100310024539000_8.2.e001511.49","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40364-018-0116-0","article-title":"Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy","volume":"6","author":"Wang","year":"2018","journal-title":"Biomark Res"},{"key":"2025100310024539000_8.2.e001511.50","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0040"},{"key":"2025100310024539000_8.2.e001511.51","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1319"},{"key":"2025100310024539000_8.2.e001511.52","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15644"},{"key":"2025100310024539000_8.2.e001511.53","doi-asserted-by":"crossref","DOI":"10.1016\/S0735-1097(19)31330-0","article-title":"The cardiovascular effects of chimeric antigen receptor T-cells","volume":"73","author":"Alvi","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2025100310024539000_8.2.e001511.54","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-694356"},{"key":"2025100310024539000_8.2.e001511.55","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-281931"},{"key":"2025100310024539000_8.2.e001511.56","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0698"},{"key":"2025100310024539000_8.2.e001511.57","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-793141"},{"key":"2025100310024539000_8.2.e001511.58","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-793760"},{"key":"2025100310024539000_8.2.e001511.59","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"2025100310024539000_8.2.e001511.60","unstructured":"Maude SG , Pulsipher SA , Rives MA . Analysis of safety data from 2 multicenter trials of ctl019 in pediatric and young adult patients with relapsed\/refractory (R\/R) B-Cell acute lymphoblastic leukemia (B-ALL) in 22nd Congress of the European-Hematology-Association. 22nd Congress of the European Hematology Association; 06\/24\/2017, Madrid, Spain, 2017:197\u20138.doi:https:\/\/library.ehaweb.org\/eha\/2017\/22nd\/181804\/shannon.maude.analysis.of.safety.data.from.2.multicenter.trials.of.ctl019.in.html?f=m3e1181l15532"},{"key":"2025100310024539000_8.2.e001511.61","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.06.019"},{"key":"2025100310024539000_8.2.e001511.62","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1083-8791(00)70002-4","article-title":"Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients","volume":"6","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025100310024539000_8.2.e001511.63","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1182\/asheducation-2001.1.392","article-title":"Preventing opportunistic infections after hematopoietic stem cell transplantation: the centers for disease control and prevention, infectious diseases Society of America, and American Society for blood and marrow transplantation practice guidelines and beyond","author":"Sullivan","year":"2001","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2025100310024539000_8.2.e001511.64","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704423"},{"key":"2025100310024539000_8.2.e001511.65","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"key":"2025100310024539000_8.2.e001511.66","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21203"},{"key":"2025100310024539000_8.2.e001511.67","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12054"},{"key":"2025100310024539000_8.2.e001511.68","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(09)70175-6"},{"key":"2025100310024539000_8.2.e001511.69","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jpeds.2017.08.071","article-title":"The effectiveness of trivalent inactivated influenza vaccine in children with acute leukemia","volume":"191","author":"Sykes","year":"2017","journal-title":"J Pediatr"},{"key":"2025100310024539000_8.2.e001511.70","first-page":"6044","article-title":"Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin\u2019s lymphoma patients treated with rituximab-containing regimens.","volume":"186","author":"Bedognetti","year":"2011","journal-title":"J.i."},{"key":"2025100310024539000_8.2.e001511.71","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1002\/cncr.32411","article-title":"Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma","volume":"125","author":"Abramson","year":"2019","journal-title":"Cancer"},{"key":"2025100310024539000_8.2.e001511.72","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.bbmt.2020.04.008","article-title":"Chimeric antigen receptor T cell therapy during the COVID-19 pandemic","volume":"26","author":"Bachanova","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025100310024539000_8.2.e001511.73","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-769208"},{"key":"2025100310024539000_8.2.e001511.74","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709919"},{"key":"2025100310024539000_8.2.e001511.75","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"2025100310024539000_8.2.e001511.76","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ymthe.2016.11.011","article-title":"The Flipside of the power of engineered T cells: observed and potential toxicities of genetically modified T cells as therapy","volume":"25","author":"Bedoya","year":"2017","journal-title":"Mol Ther"},{"key":"2025100310024539000_8.2.e001511.77","unstructured":"Common terminology criteria forAdverse events (CTCAE), 2010 United States Department of Health and Human Services. Available: https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf"},{"key":"2025100310024539000_8.2.e001511.78","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2019.1585238"},{"key":"2025100310024539000_8.2.e001511.79","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008226"},{"key":"2025100310024539000_8.2.e001511.80","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0571-y"},{"key":"2025100310024539000_8.2.e001511.81","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1182\/bloodadvances.2019001304","article-title":"Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial","volume":"4","author":"Schuster","year":"2020","journal-title":"Blood Adv"},{"key":"2025100310024539000_8.2.e001511.82","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-881722"},{"key":"2025100310024539000_8.2.e001511.83","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0036-4"},{"key":"2025100310024539000_8.2.e001511.84","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in car T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"key":"2025100310024539000_8.2.e001511.85","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000035"},{"key":"2025100310024539000_8.2.e001511.86","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1080\/17474086.2016.1183479","article-title":"Medical management of side effects related to CAR T cell therapy in hematologic malignancies","volume":"9","author":"Namuduri","year":"2016","journal-title":"Expert Rev Hematol"},{"key":"2025100310024539000_8.2.e001511.87","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S150524"},{"key":"2025100310024539000_8.2.e001511.88","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-711903"},{"key":"2025100310024539000_8.2.e001511.89","doi-asserted-by":"crossref","DOI":"10.1016\/j.soncn.2019.08.010","article-title":"Management principles associated with cytokine release syndrome","volume":"35","author":"Baer","year":"2019","journal-title":"Semin Oncol Nurs"},{"key":"2025100310024539000_8.2.e001511.90","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0343-9"},{"key":"2025100310024539000_8.2.e001511.91","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.10.038"},{"key":"2025100310024539000_8.2.e001511.92","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0904569"},{"key":"2025100310024539000_8.2.e001511.93","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000010455","article-title":"Arthritis of large joints shown as a rare clinical feature of cytokine release syndrome after chimeric antigen receptor T cell therapy: a case report","volume":"97","author":"Wang","year":"2018","journal-title":"Medicine"},{"key":"2025100310024539000_8.2.e001511.94","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.0287"},{"key":"2025100310024539000_8.2.e001511.95","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/EDBK_238691","article-title":"The other side of car T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden","volume":"39","author":"Santomasso","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2025100310024539000_8.2.e001511.96","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85309"},{"key":"2025100310024539000_8.2.e001511.97","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41434-018-0019-6","article-title":"Fludarabine and neurotoxicity in engineered T-cell therapy","volume":"25","author":"Lowe","year":"2018","journal-title":"Gene Ther"},{"key":"2025100310024539000_8.2.e001511.98","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0028"},{"key":"2025100310024539000_8.2.e001511.99","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1182\/blood.V128.22.586.586","article-title":"Decreased rates of severe CRS seen with early intervention strategies for CD19 CAR-T cell toxicity management","volume":"128","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"2025100310024539000_8.2.e001511.100","unstructured":"Kadauke S , Myers RM , Li Y , et al . Risk-Adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: a prospective clinical trial. J Clin Oncol 2020;in press doi:<br>"},{"key":"2025100310024539000_8.2.e001511.101","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.3358.3358","article-title":"Tocilizumab-Refractory Cytokine Release Syndrome (CRS) Triggered By Chimeric Antigen Receptor (CAR)-Transduced T Cells May Have Distinct Cytokine Profiles Compared to Typical CRS","volume":"128","author":"Ishii","year":"2016","journal-title":"Blood"},{"key":"2025100310024539000_8.2.e001511.102","doi-asserted-by":"crossref","first-page":"8011","DOI":"10.1200\/JCO.2020.38.15_suppl.8011","article-title":"Prognostic impact of dose, duration, and timing of corticosteroid therapy in patients with large B-cell lymphoma treated with standard of care axicabtagene ciloleucel (Axi-cel)","volume":"38","author":"Strati","year":"2020","journal-title":"JCO"},{"key":"2025100310024539000_8.2.e001511.103","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1111\/bjh.16155","article-title":"Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy","volume":"187","author":"Hashmi","year":"2019","journal-title":"Br J Haematol"},{"key":"2025100310024539000_8.2.e001511.104","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2015.1.190"},{"key":"2025100310024539000_8.2.e001511.105","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00005-015-0343-0","article-title":"Clinical and In Vitro Studies on Impact of High-Dose Etoposide Pharmacokinetics Prior Allogeneic Hematopoietic Stem Cell Transplantation for Childhood Acute Lymphoblastic Leukemia on the Risk of Post-Transplant Leukemia Relapse","volume":"63","author":"Sobiak","year":"2015","journal-title":"Arch Immunol Ther Exp"},{"key":"2025100310024539000_8.2.e001511.106","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1302282"},{"key":"2025100310024539000_8.2.e001511.107","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03279"},{"key":"2025100310024539000_8.2.e001511.108","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1172\/JCI130059","article-title":"Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients","volume":"130","author":"Ishii","year":"2020","journal-title":"J Clin Invest"},{"key":"2025100310024539000_8.2.e001511.109","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.0225"},{"key":"2025100310024539000_8.2.e001511.110","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02104"},{"key":"2025100310024539000_8.2.e001511.111","doi-asserted-by":"crossref","first-page":"5702","DOI":"10.1182\/blood.V128.22.5702.5702","article-title":"Posterior reversible encephalopathy syndrome (PRES) after infusion of Anti-Bcma CAR T cells (CART-BCMA) for multiple myeloma: successful treatment with cyclophosphamide","volume":"128","author":"Garfall","year":"2016","journal-title":"Blood"},{"key":"2025100310024539000_8.2.e001511.112","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13045-016-0299-5","article-title":"Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy","volume":"9","author":"Hu","year":"2016","journal-title":"J Hematol Oncol"},{"key":"2025100310024539000_8.2.e001511.113","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61403-3"},{"key":"2025100310024539000_8.2.e001511.114","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/jnci\/djz017","article-title":"Car T-cell associated neurotoxicity: mechanisms, clinicopathologic correlates, and future directions","volume":"111","author":"Hunter","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"2025100310024539000_8.2.e001511.115","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-NB2017-161"},{"key":"2025100310024539000_8.2.e001511.116","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4441"},{"key":"2025100310024539000_8.2.e001511.117","doi-asserted-by":"crossref","unstructured":"Schuster SJ et al . Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma 2018;380:45\u201356.doi:10.1056\/NEJMoa1804980","DOI":"10.1056\/NEJMoa1804980"},{"key":"2025100310024539000_8.2.e001511.118","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-12-893396"},{"key":"2025100310024539000_8.2.e001511.119","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/jnen\/nly064","article-title":"Neuropathology of a case with fatal car T-cell-associated cerebral edema","volume":"77","author":"Torre","year":"2018","journal-title":"J Neuropathol Exp Neurol"},{"key":"2025100310024539000_8.2.e001511.120","unstructured":"Britton JW et al . Electroencephalography (EEG): An Introductory Text and Atlas of Normal and Abnormal Findings in Adults, Children, and Infants. In: EK SL , Frey LC , eds. Chicago, 2016."},{"key":"2025100310024539000_8.2.e001511.121","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708566"},{"key":"2025100310024539000_8.2.e001511.122","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.08.003"},{"key":"2025100310024539000_8.2.e001511.123","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2016.03.005"},{"key":"2025100310024539000_8.2.e001511.124","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001694"},{"key":"2025100310024539000_8.2.e001511.125","doi-asserted-by":"crossref","first-page":"204062072090289","DOI":"10.1177\/2040620720902899","article-title":"Safety and efficacy of axicabtagene ciloleucel in refractory large B-cell lymphomas","volume":"11","author":"Riedell","year":"2020","journal-title":"Ther Adv Hematol"},{"key":"2025100310024539000_8.2.e001511.126","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13045-016-0299-5","article-title":"Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy","volume":"9","author":"Hu","year":"2016","journal-title":"J Hematol Oncol"},{"key":"2025100310024539000_8.2.e001511.127","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-887067"},{"key":"2025100310024539000_8.2.e001511.128","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"2025100310024539000_8.2.e001511.129","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","article-title":"Her2-Specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial","volume":"3","author":"Ahmed","year":"2017","journal-title":"JAMA Oncol"},{"key":"2025100310024539000_8.2.e001511.130","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa0984"},{"key":"2025100310024539000_8.2.e001511.131","article-title":"Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","author":"Logue","year":"2020","journal-title":"Haematologica"},{"key":"2025100310024539000_8.2.e001511.132","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1697814"},{"key":"2025100310024539000_8.2.e001511.133","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0487-3"},{"key":"2025100310024539000_8.2.e001511.134","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.311"},{"key":"2025100310024539000_8.2.e001511.135","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2018.00009"},{"key":"2025100310024539000_8.2.e001511.136","unstructured":"Common terminology criteria for adverse events (CTCAE) v5.0, 2017 United States Department of Health and Human Services. Available: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf"},{"key":"2025100310024539000_8.2.e001511.137","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.05.014"},{"key":"2025100310024539000_8.2.e001511.138","doi-asserted-by":"crossref","first-page":"v277","DOI":"10.1093\/annonc\/mdq200","article-title":"Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO clinical practice guidelines","volume":"21 Suppl 5","author":"Bovelli","year":"2010","journal-title":"Ann Oncol"},{"key":"2025100310024539000_8.2.e001511.139","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2014.07.012"},{"key":"2025100310024539000_8.2.e001511.140","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.11.049"},{"key":"2025100310024539000_8.2.e001511.141","doi-asserted-by":"crossref","first-page":"421","DOI":"10.4329\/wjr.v4.i10.421","article-title":"Equilibrium radionuclide angiocardiography: its usefulness in current practice and potential future applications","volume":"4","author":"Mitra","year":"2012","journal-title":"World J Radiol"},{"key":"2025100310024539000_8.2.e001511.142","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1542\/peds.89.5.942","article-title":"Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the cardiology Committee of the Childrens cancer Study Group","volume":"89","author":"Steinherz","year":"1992","journal-title":"Pediatrics"},{"key":"2025100310024539000_8.2.e001511.143","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2004.12.032"},{"key":"2025100310024539000_8.2.e001511.144","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv320"},{"key":"2025100310024539000_8.2.e001511.145","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.08.1038"},{"key":"2025100310024539000_8.2.e001511.146","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2005.071282"},{"key":"2025100310024539000_8.2.e001511.147","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.02.037"},{"key":"2025100310024539000_8.2.e001511.148","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2004.05.076"},{"key":"2025100310024539000_8.2.e001511.149","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-016-6711-0"},{"key":"2025100310024539000_8.2.e001511.150","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.121"},{"key":"2025100310024539000_8.2.e001511.151","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.013777"},{"key":"2025100310024539000_8.2.e001511.152","doi-asserted-by":"crossref","first-page":"S4282","DOI":"10.21037\/jtd.2018.08.15","article-title":"Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity","volume":"10","author":"Michel","year":"2018","journal-title":"J Thorac Dis"},{"key":"2025100310024539000_8.2.e001511.153","doi-asserted-by":"crossref","DOI":"10.1177\/1179546817697983","article-title":"Diagnostic strategies for early recognition of cancer Therapeutics-Related cardiac dysfunction","volume":"11","author":"Manrique","year":"2017","journal-title":"Clin Med Insights Cardiol"},{"key":"2025100310024539000_8.2.e001511.154","doi-asserted-by":"publisher","DOI":"10.1016\/j.lab.2005.02.003"},{"key":"2025100310024539000_8.2.e001511.155","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000002053"},{"key":"2025100310024539000_8.2.e001511.156","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-802413"},{"key":"2025100310024539000_8.2.e001511.157","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)15326-3"},{"key":"2025100310024539000_8.2.e001511.158","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000000701"},{"key":"2025100310024539000_8.2.e001511.159","doi-asserted-by":"crossref","first-page":"54","DOI":"10.15420\/ecr.2016:4:2","article-title":"Uric acid and cardiovascular disease: an update","volume":"11","author":"Muiesan","year":"2016","journal-title":"Eur Cardiol"},{"key":"2025100310024539000_8.2.e001511.160","doi-asserted-by":"publisher","DOI":"10.2174\/138161205774913255"},{"key":"2025100310024539000_8.2.e001511.161","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.drudis.2018.02.012","article-title":"Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts","volume":"23","author":"Zheng","year":"2018","journal-title":"Drug Discov Today"},{"key":"2025100310024539000_8.2.e001511.162","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012213432504"},{"key":"2025100310024539000_8.2.e001511.163","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02374.x"},{"key":"2025100310024539000_8.2.e001511.164","first-page":"305","article-title":"A review of warfarin dosing and monitoring","volume":"14","author":"Kuruvilla","year":"2001","journal-title":"Proc"},{"key":"2025100310024539000_8.2.e001511.165","first-page":"635","article-title":"Warfarin therapy: evolving strategies in anticoagulation","volume":"59","author":"Horton","year":"1999","journal-title":"Am Fam Physician"},{"key":"2025100310024539000_8.2.e001511.166","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr392"},{"key":"2025100310024539000_8.2.e001511.167","doi-asserted-by":"crossref","first-page":"e452","DOI":"10.1016\/S1470-2045(16)30369-2","article-title":"International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"17","author":"Farge","year":"2016","journal-title":"Lancet Oncol"},{"key":"2025100310024539000_8.2.e001511.168","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0084"},{"key":"2025100310024539000_8.2.e001511.169","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0073"},{"key":"2025100310024539000_8.2.e001511.170","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-139-11-200312020-00007"},{"key":"2025100310024539000_8.2.e001511.171","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)00267-3"},{"key":"2025100310024539000_8.2.e001511.172","doi-asserted-by":"publisher","DOI":"10.4065\/70.8.725"},{"key":"2025100310024539000_8.2.e001511.173","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110676200"},{"key":"2025100310024539000_8.2.e001511.174","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4049\/jimmunol.163.1.111","article-title":"Induction of cyclooxygenase-2 on activated T lymphocytes: regulation of T cell activation by cyclooxygenase-2 inhibitors","volume":"163","author":"I\u00f1iguez","year":"1999","journal-title":"J Immunol"},{"key":"2025100310024539000_8.2.e001511.175","doi-asserted-by":"publisher","DOI":"10.1186\/2162-3619-1-36"},{"key":"2025100310024539000_8.2.e001511.176","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.02.017"},{"key":"2025100310024539000_8.2.e001511.177","doi-asserted-by":"publisher","DOI":"10.1038\/nri3795"},{"key":"2025100310024539000_8.2.e001511.178","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2017.03.003"},{"key":"2025100310024539000_8.2.e001511.179","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3389\/fimmu.2014.00626","article-title":"Immunoglobulin replacement therapy in secondary hypogammaglobulinemia","volume":"5","author":"Compagno","year":"2014","journal-title":"Front Immunol"},{"key":"2025100310024539000_8.2.e001511.180","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.09.023"},{"key":"2025100310024539000_8.2.e001511.181","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26914","article-title":"Hypogammaglobulinemia due to CAR T-cell therapy","volume":"65","author":"Doan","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"2025100310024539000_8.2.e001511.182","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28092","article-title":"Subcutaneous immunoglobulin replacement following CD19\u2010specific chimeric antigen receptor T\u2010cell therapy for B\u2010cell acute lymphoblastic leukemia in pediatric patients","volume":"67","author":"Arnold","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"2025100310024539000_8.2.e001511.183","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100596","article-title":"CAR-T - and a side order of IgG, to go? - Immunoglobulin replacement in patients receiving CAR-T cell therapy","volume":"38","author":"Hill","year":"2019","journal-title":"Blood Rev"},{"key":"2025100310024539000_8.2.e001511.184","unstructured":"FDA, U . Information About Immune Globulin (Human) Product Shortage U.S. FDA, 2019."},{"key":"2025100310024539000_8.2.e001511.185","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0006"},{"key":"2025100310024539000_8.2.e001511.186","doi-asserted-by":"crossref","first-page":"796","DOI":"10.2215\/CJN.12871117","article-title":"Chimeric antigen receptor T cell therapy and the kidney","volume":"13","author":"Jhaveri","year":"2018","journal-title":"CJASN"},{"key":"2025100310024539000_8.2.e001511.187","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500404662"},{"key":"2025100310024539000_8.2.e001511.188","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11575"},{"key":"2025100310024539000_8.2.e001511.189","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.31"},{"key":"2025100310024539000_8.2.e001511.190","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0767-x"},{"key":"2025100310024539000_8.2.e001511.191","doi-asserted-by":"crossref","first-page":"10523","DOI":"10.1200\/JCO.2017.35.15_suppl.10523","article-title":"Patient-Reported quality of life (QOL) following CTL019 in pediatric and young adult patients (PTS) with relapsed\/refractory (r\/r) B-cell acute lymphoblastic leukemia (B-ALL)","volume":"35","author":"Dietz","year":"2017","journal-title":"JCO"},{"key":"2025100310024539000_8.2.e001511.192","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.09.037"},{"key":"2025100310024539000_8.2.e001511.193","doi-asserted-by":"crossref","first-page":"166","DOI":"10.21037\/atm.2018.03.28","article-title":"Financial toxicity and implications for cancer care in the era of molecular and immune therapies","volume":"6","author":"Tran","year":"2018","journal-title":"Ann Transl Med"},{"key":"2025100310024539000_8.2.e001511.194","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1001\/jamapediatrics.2018.2530","article-title":"Long-Term survival and value of chimeric antigen receptor T-cell therapy for pediatric patients with relapsed or refractory leukemia","volume":"172","author":"Whittington","year":"2018","journal-title":"JAMA Pediatr"},{"key":"2025100310024539000_8.2.e001511.195","first-page":"379","article-title":"The potential impact of car T-cell treatment delays on Society","volume":"25","author":"Thornton Snider","year":"2019","journal-title":"Am J Manag Care"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-001511","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T17:03:04Z","timestamp":1759510984000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-001511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":195,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,12,16]]},"published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1136\/jitc-2020-001511"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-001511","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]}}}